Ruboxistaurin: PKC-β inhibition for complications of diabetes

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.10, Iss.17, 2009-12, pp. : 2913-2925

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The protein kinase C-β inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications

By Vinik Aaron

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 12, 2005-12 ,pp. : 1547-1559

Informa Healthcare

Access to resources Recommend Favorite

Clinical safety of the selective PKC-&bgr; inhibitor, ruboxistaurin

By McGill Janet B King George L Berg Paul H Price Karen L Kles Keri A Bastyr Edward J Hyslop David L

Expert Opinion on Drug Safety, Vol. 5, Iss. 6, 2006-11 ,pp. : 835-845

Informa Healthcare

Access to resources Recommend Favorite

Exploring the economic impact of diabetes complications

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 589, 2009-01 ,pp. : 5-6

Adis International

Access to resources Recommend Favorite

Cerebrovascular Complications of Diabetes: Focus on Stroke

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 12, Iss. 2, 2012-06 ,pp. : 148-158

Bentham Science Publishers

Access to resources Recommend Favorite

Ruboxistaurin: LY 333531

By Adis International Limited

Drugs in R&D, Vol. 8, Iss. 3, 2007-01 ,pp. : 193-199

Adis International

Access to resources Recommend Favorite